Key facts
- This page summarizes Christopher B. Ehrlich's Form 4 filing for CERO THERAPEUTICS HOLDINGS, INC. (CERO).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 02 Jun 2025, 17:04.
Christopher B. Ehrlich - 30 May 2025 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)
- Signature
- /s/ Andrew Kucharchuk, Attorney-in-Fact
- Issuer symbol
- CERO
- Transactions as of
- 30 May 2025
- Net transaction value
- $0
- Form type
- 4
- Filing time
- 02 Jun 2025, 17:04:25 UTC
- Previous filing
- 06 Mar 2025
- Next filing
- 09 Jan 2026
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
Christopher B. Ehrlich filed Form 4 for CERO THERAPEUTICS HOLDINGS, INC. (CERO) on 02 Jun 2025.
Change
- Previous filing in this sequence was filed on 06 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001293973
Primary reporting owner
Ehrlich Christopher B
- Relationship
- Chairman and CEO, Director
- Address
- CERO THERAPEUTICS HOLDINGS, INC., 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO
- Signature
- /s/ Andrew Kucharchuk, Attorney-in-Fact
- Signature date
- 02 Jun 2025
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
CERO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +61,843
- Change %
- Price
- $0.000000
- Shares after
- 61,842
- Date
- 30 May 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 61,842
- Exercise price
- $0.4454
- Footnotes
- F1
* indicates a reported price that failed the local validity check.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Represents the 1/3 time-based portion of an award of options to purchase 185,529 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through December 4, 2025, with the remaining portion subject to performance conditions. |
Remarks:
Exhibit 24 - Power of Attorney.